Skip to content

Early Multimodal Neuromonitoring For Spontaneous Intracerebral Hemorrhage (ICH)

Early Multimodal Neuromonitoring Parameters as Prognostic Factors For Critically Ill Spontaneous ICH Patients

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05501613
Enrollment
65
Registered
2022-08-15
Start date
2015-01-31
Completion date
2023-02-01
Last updated
2023-02-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cerebral Perfusion Pressure, Critically Ill, Intracerebral Hemorrhage, Intracranial Pressure, Prognostic

Brief summary

The investigators intend to assess the predictive value of early (first 48 hours) multimodal neuromonitoring parameters concerning late survival in critically ill intracerebral hemorrhage (ICH) patients.

Detailed description

Retrospective observational study based on analyzing the first 48 hours of the multimodal neuromonitoring signal, from spontaneous ICH patients, whose treatment includes invasive intraparenchymal neuromonitoring, treated from January 2015 to September 2021 in a tertiary hospital.

Interventions

Invasive Multimodal Neuromonitoring

Sponsors

Universidade do Porto
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Spontaneous Intracerebral Hemorrhage * ICU admission * Need of Sedation and Ventilatory Support * Need of Intracerebral Neuromonitoring

Exclusion criteria

* Etiology for Intracerebral hemorrhage such as tumor, vascular malformation, ischemic transformation.

Design outcomes

Primary

MeasureTime frameDescription
Survival1 and 6 months1 and 6 months survival
Functional Outcome6 month6 month functional outcome with Modified Rankin Scale - 0 (No symptoms); 1 (No significant disability); 2 (Slight disability); 3 (Moderate disability); 4 (Moderately Severe Disability); 5 (Severe Disability); 6 (Dead).

Countries

Portugal

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 23, 2026